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Abstract 
 
Background: Mismatch repair (MMR) gene activity may be associated with prostate 
cancer (PC) risk and outcomes. This study evaluated whether single nucleotide 
polymorphisms (SNPs) in key MMR genes are related to PC outcomes. 
 
Methods: Data from two population-based case-control studies of PC among 
Caucasian and African-American men residing in King County, Washington were 
combined for this analysis. Cases (n=1,458) were diagnosed with PC in 1993-96 or 
2002-05 and identified via the Seattle-Puget Sound SEER cancer registry. Controls 
(n=1,351) were age-matched to cases and identified via random digit dialing. Logistic 
regression was used to assess the relationship between haplotype-tagging SNPs and 
PC risk and disease aggressiveness. Cox proportional hazards regression was used to 
assess the relationship between SNPs and PC recurrence and PC-specific death. 
 
Results: Nineteen SNPs were evaluated in the key MMR genes: five in MLH1, 10 in 
MSH2, and 4 in PMS2. Among Caucasian men, one SNP in MLH1 (rs9852810) was 
associated with: overall PC risk (OR=1.21, 95% CI=1.02, 1.44; p=0.03), more 
aggressive PC (OR=1.49, 95% CI=1.15-1.91; p<0.01), and PC recurrence (HR=1.83, 
95% CI=1.18, 2.86; p<0.01), but not PC-specific mortality. A non-synonymous coding 
SNP in MLH1, rs1799977 (I219V), was also found to be associated with more 
aggressive disease. These results did not remain significant after adjusting for multiple 
comparisons.  
 
Conclusion: This population-based case-control study provides evidence for a possible 
association with a gene variant in MLH1 in relation to risk of overall PC, more 
aggressive disease, and PC recurrence, which warrants replication. 
Introduction 
 
 This year alone, an estimated 30,000 deaths will occur among US men due to 
prostate cancer [1]. Established risk factors for PC (age, race/ethnicity, and a family 
history of PC) and features of more aggressive disease (e.g., higher Gleason score, 
advanced tumor stage, and high prostate-specific antigen [PSA] levels) are not 
adequate to predict which cases will become life-threatening; therefore, active 
investigation is underway to identify biomarkers that will enhance the ability to identify 
patients at higher risk for adverse PC outcomes [2]. In this analysis, we evaluated the 
association of variants in key mismatch repair (MMR) genes, MSH2 (on 2p22-21), 
MLH1 (on 3p21), and PMS2 (on 7p22), in relation to overall PC risk, risk of more 
aggressive disease, PC recurrence, and PC-specific mortality. 
 Mutations in MMR genes (MLH1, MSH2, MSH3, MSH6, PMS1, and PMS2) can 
lead to instability of microsatellites (MSI) and failure to repair DNA damage during DNA 
replication. This damaged DNA can accumulate and eventually lead to the development 
of neoplasms, such as hereditary nonpolyposis colon cancer (HNPCC), which is 
characterized by mutations in five microsatellites [3]. A number of studies have reported 
more MSI in PC tumor tissue compared to normal prostatic tissue [4-9], but some PC 
tissue studies have found a low frequency of MSI [10-14]. In addition, reduction or loss 
of MMR protein expression has been found in human PC cell lines, such as LNCaP, 
PC-3 and DU145 [15-20]. And some studies, but not all, have correlated hMSH2 
immunohistochemical staining intensity with a higher Gleason score and lower disease-
free survival [21-23]. Recently, Norris et al. found elevated levels of PMS2 in the 
prostate tumor tissue of patients who recurred compared with non-recurrent patients 
[24].  
 The non-synonymous coding SNP rs1799977 in MLH1 (also referred to as Ile-
219Val or I219V) has been evaluated in two studies of PC risk, with mixed results.  
Using 275 PC sibships and 556 unrelated controls, Burmester et al. found the rare allele 
of the SNP rs1799977 was significantly associated with PC [25]. Fredriksson et al., 
however, found no difference in allele frequency for rs1799977 between 121 patients 
with hereditary PC (allele frequency=54.5%), unselected patients with PC (54.0%), 202 
patients with benign prostatic hyperplasia (54.0%), and 200 controls (55.0%) [26]. 
 In light of these provocative but inconclusive findings, this study evaluated the 
association between variants in the key MMR genes and the risk of PC and PC 
outcomes. 
 
Methods 
 
Study Population 
 
 Data were combined for this analysis from two population-based case-control 
studies of risk factors for PC among Caucasian and African-American men residing in 
King County, Washington, described previously [27-28]. Both studies ascertained cases 
from the Seattle-Puget Sound Surveillance Epidemiology and End Results (SEER) 
cancer registry. The first study included 753 cases diagnosed between January 1, 1993 
and December 31, 1996 who were 40 to 64 years of age at diagnosis. The second 
study included 1,001 cases diagnosed between January 1, 2002 and December 31, 
2005 who were 35 to 74 years of age at diagnosis. Controls (n=703 for the first study, 
n=942 for the second study) were men without a self-reported history of PC, who were 
recruited via random digit dialing (RDD) during the same ascertainment period and from 
the same underlying general population as the cases; they were frequency matched to 
cases by five-year age groups. Among eligible subjects ascertained for the first study, 
82% of cases and 75% of controls participated in the study interview, and of these 
participants, 84% of cases and 80% of controls provided a blood sample. Among 
eligible subjects ascertained for the second study, 75% of cases and 63% of controls 
participated in the study interview, and of these participants, 83% of cases and 84% of 
controls provided a blood sample. After combining these two studies, there were 1,457 
PC cases and 1,351 controls with DNA available for the analysis.  
 Background information was collected from participants at the time of interview 
and included demographic and lifestyle factors, medical history, PC screening history, 
and family history of PC. This information was assessed prior to date of diagnosis for 
cases and prior to a pre-assigned reference date for controls. Clinical information such 
as Gleason score, tumor stage, serum PSA level at diagnosis, and primary treatment 
was obtained from the cancer registry. Patient files have been linked to the registry on a 
regular basis to obtain vital status and primary cause of death of cases; death 
certificates are requested from the state to confirm underlying cause of death. In 2004, 
a follow-up survey was sent to 631 of the cases from the first study, 82% of whom 
responded, to assess secondary treatment(s) and evidence for PC recurrence or 
progression.  
 The Institutional Review Board (IRB) of the Fred Hutchinson Cancer Research 
Center approved study procedures and materials, and written informed consent was 
obtained from all study participants. Genotyping was approved by the National Human 
Genome Research Institute’s IRB. 
 
TagSNP Selection and Genotyping  
 
 DNA samples were genotyped for 20 single nucleotide polymorphisms (SNPs) in 
the MLH1, MSH2, and PMS2 genes. The SNPs were selected using the Genome 
Variation Server (gvs.gs.washington.edu/gvs) to cover the genes as haplotype-tagging 
SNPs. The Applied Biosystems (ABI) SNPlex® Genotyping System was used for 
genotyping and proprietary GeneMapper® software was used for allele assignment 
(www.appliedbiosystems.com). Discrimination of the specific SNP allele was carried out 
with the ABI 3730xl DNA Analyzer and is based on the presence of a unique sequence 
assigned to the original allele-specific oligonucleotide. Quality control included 
genotyping of 144 blind duplicate samples distributed across all genotyping batches. 
There was ≥99% agreement between blinded samples for all SNP genotypes. Each 
batch of DNA aliquots genotyped incorporated similar numbers of case and control 
samples, and laboratory personnel were blinded to the case-control status of samples. 
Genotype frequencies in MLH1, MSH2, and PMS2 were evaluated among Caucasian 
and African-American controls separately; all SNPs were consistent with the expected 
proportions under Hardy-Weinberg, except for rs12112229 among Caucasians, and so 
this SNP was removed from the analysis.  
 
Statistical Methods 
 
 Logistic regression was used to calculate odds ratios (ORs) and 95% confidence 
intervals (CIs) to estimate the relative risk of PC among cases relative to controls for 
each SNP genotype. Polytomous logistic regression was used to calculate ORs and 
95% CIs to estimate the relative risk of more aggressive and less aggressive PC 
relative to controls for each SNP genotype. More aggressive PC was defined by a 
Gleason score of 7(4+3) or 8-10, regional or distant tumor stage, or a diagnostic PSA 
value >20 ng/mL. Codominant and dominant genetic models were considered for each 
SNP. All models were adjusted for age at reference date, and tested for possible 
confounding by PC screening history and/or family history of PC. In addition, permuted 
p-values were calculated to adjust for multiple comparisons, as described previously 
[29]. 
 Cox proportional hazards regression was used to estimate hazard ratios and 
95% CIs to assess the relationship between the SNPs found to be significantly 
associated with aggressive PC and recurrence or death from PC. The analyses of 
recurrence were restricted to cases diagnosed with local or regional stage disease and 
who either subsequently died of PC (prior to the follow-up survey) or completed a 
follow-up survey, which provided recurrence information and consent to obtain medical 
records. Recurrence was defined as at least one of the following from self-report and/or 
medical records: a positive bone scan, CT, MRI, or biopsy showing PC after primary 
treatment; use of secondary therapy (androgen deprivation therapy [ADT], external 
beam radiation therapy, cryotherapy, or chemotherapy); an elevated PSA (≥0.2 ng/mL) 
after radical prostatectomy; an elevated PSA after radiation therapy (nadir PSA +2 
ng/mL); a rising PSA while on primary ADT; treatment for evidence of progressive 
disease that was initiated >12 months after diagnosis in patients on active surveillance; 
or a self-reported physician’s diagnosis of disease recurrence/progression. Time from 
diagnosis until recurrence was calculated as the difference between the date of 
diagnosis and the earliest date of evidence of recurrence: date of death from PC, date 
of recurrence or progression abstracted from medical records, date of recurrence from 
the follow-up survey, or, for those censored, the end of the year during which the follow-
up survey was collected (December 31, 2005). For men who died of PC before 
December 31, 2005, date of recurrence was imputed to be similar to dates of 
recurrence for comparable subjects. The analyses of PC death included all cases. The 
censoring date for members last known to be alive was the date of the last vital status 
update from the cancer registry (December 1, 2008). The proportional hazards models 
were adjusted for age and tested for possible confounding by PC screening history or a 
family history of PC, and recalculated including only cases who received radical 
prostatectomy as primary therapy. 
  Most analyses were performed in SAS® version 9.1.3 (SAS Institute, Cary, NC). 
Hardy-Weinberg equilibrium was calculated in STATA/SE® 10.0 for Windows 
(StataCorp, College Station, TX).  
 
 
 
Results 
 
 Among the 1,458 cases and 1,351 controls, a higher proportion of cases than 
controls were African-American (10.2% vs. 6.3%, respectively; Table 1), had a first-
degree relative with PC (21.5% vs. 11.3%), and reported having a PSA or DRE 
screening test in the five years prior to diagnosis or reference date (89.3% and 86.5%).  
 Nineteen tagSNPs were evaluated: 5 in MLH1, 10 in MSH2, and 4 in PMS2. 
Among Caucasian men, one SNP in MLH1 (rs9852810) was associated with overall PC 
risk (OR=1.21, 95% CI=1.02, 1.44, p=0.03; Table 2 and supplementary data). 
Rs9852810 and another SNP in MLH1, rs1799977, were associated with more 
aggressive PC among Caucasian men when aggressive cases were compared with 
controls (rs9852810: ORCT+CC=1.49, 95% CI=1.15, 1.91, p<0.01; rs1799977: 
ORGA+AA=1.35, 95%CI=1.08, 1.69, p=0.03; Table 2) and when aggressive cases were 
compared to less aggressive cases (rs9852810: ORCT+CC=1.34, 95% CI=1.03, 1.75, 
p=0.03; rs1799977: ORCT+CC=1.33, 95% CI=1.05, 1.69, p=0.02; data not shown). After 
adjustment for multiple comparisons using permutation p-values, rs9852810 did not 
remain significantly associated with overall PC risk (pperm=0.22); in addition the 
associations between rs9852810 and rs1799977 with more aggressive disease did not 
attain statistical significance (when compared to controls, pperm=0.09 for both SNPs). 
The association with overall PC risk and with disease aggressiveness remained similar 
after adjustment for a first-degree relative with PC or having a PC screening test in the 
five years prior to reference date. Similar analyses among African-American men 
revealed no associations between any SNP genotypes and overall PC risk or disease 
aggressiveness (Table 2).  
 Among the 469 Caucasian cases diagnosed with local or regional disease who 
completed a follow-up survey or died of prostate cancer before December 31, 2005, 143 
recurred. Rs9852810, was associated with PC recurrence in Caucasians (110 out of 
320 [34.4%] cases with the putative risk genotype and 24 out of 115 [20.9%] cases with 
the homozygous wild-type genotype recurred; HRGA+AA=1.83, 95%CI=1.18, 2.86, 
p<0.01; Table 3). Rs1799977 was not associated with PC recurrence and neither SNP 
was associated with PC-specific mortality (Table 3). 
 
Discussion 
 
 In this population-based case-control study of tagSNPs in key MMR genes 
(MLH1, MSH2, and PMS2), we found the SNP rs9852810 in MLH1 to be associated 
with a modest increase in overall PC risk, risk of more aggressive PC, and PC 
recurrence. This intronic SNP is in perfect LD with several other SNPs near the start 
codon of MLH1 (such as rs11129748). To our knowledge, the association with this 
variant and PC has not been evaluated previously. We also found an association 
between the non-synonymous coding SNP rs1799977 in MLH1 and more aggressive 
PC. As noted in the introduction, the association between this SNP and PC has been 
evaluated previously with mixed results [25-26]. This SNP has also recently been 
reported to be associated with breast cancer risk (OR = 1.87; 95% CI = 1.11, 3.16) [30], 
and may be associated with susceptibility to childhood acute lymphoblastic leukemia 
[31].  
 One limitation to this study is possible type I error due to multiple testing. For 
each of the 19 SNPs, we calculated 6 significance tests among Caucasians, so one 
would expect about 6 results might be due solely to chance. The main result (for 
rs9852810) did not remain significant based on a permutated p-value; however, it was 
significant in the PC risk analysis, the analysis of aggressive disease, and the analysis 
of recurrence, which lends strength to the result. If confirmed, this result lends further 
support for a potential shared susceptibility for PC and colon cancer, which is consistent 
with prior findings for a SNP in the 8q24 region that confers risk for both cancer types 
[32-33].   
 There are several strengths to this study. The data used for this analysis were 
from two population-based case-control studies, which means men with all grades and 
stages of disease, and who received a range of initial treatments, were included. In 
addition, we have over 10 years of patient follow-up to evaluate recurrence and 
progression, and clinical and patient information was available for evaluation of potential 
confounders and effect modifiers.  
 
Conclusion  
 
 Evidence from previous studies shows that loss of mismatch repair function may 
be characteristic of prostate carcinogenesis. This population-based study provides 
evidence for a possible association with a gene variant in MLH1 in relation to risk of 
overall PC, more aggressive disease, and PC recurrence, which warrants replication.  
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Table 1. Characteristics of population-based prostate cancer cases and controls 
Characteristic 
Cases 
(n=1,458) 
Controls 
(n=1,351) 
n (%) n (%) 
Age at diagnosis/reference date  
   35-49 118 (8.1) 126 (9.3)
   50-54 215 (14.8) 209 (15.5)
   55-59 357 (24.5) 358 (26.5)
   60-64 433 (29.7) 348 (25.8)
   65-69 177 (12.1) 164 (12.1)
   70-74 158 (10.8) 146 (10.8)
Race  
   Caucasian 1,309 (89.8) 1,266 (93.7)
   African-American 149 (10.2) 85 (6.3)
First-degree relative with prostate cancer  
   No 1,145 (78.5) 1,199 (88.8)
   Yes 313 (21.5) 152 (11.3)
Screening history1  
   None 157 (10.8) 182 (13.5)
   DRE only 258 (17.7) 519 (38.4)
   PSA 1,043 (71.6) 650 (48.1)
PSA value2  
   < 4.0 189 (13.0) 1,253 (92.8)
   4.0-9.9 814 (55.8) 80 (5.9)
   10.0-19.9 210 (14.4) 16 (1.2)
   ≥ 20.0 138 (9.5) 2 (0.2)
   Missing 107 (7.4)  
Gleason score  
   2-4 72 (4.9) -- --
   5-6 741 (50.8) -- --
   7 (3+4) 408 (28.0) -- --
   7 (4+3) 91 (6.2) -- --
   8-10 140 (9.6) -- --
   Missing 6 (0.4) -- --
Stage at diagnosis  
   Local 1,141 (78.3) -- --
   Regional 280 (19.2) -- --
   Distant 37 (2.5) -- --
Primary treatment  
   RP  831 (57.0) -- --
   RT 412 (28.3) -- --
   ADT  72 (4.9) -- --
   Other treatment 5 (0.3) -- --
   Active surveillance 138 (9.5) -- --
PSA=prostate-specific antigen; RP=radical prostatectomy; RT=radiation therapy; ADT=androgen 
deprivation therapy 
1 Screening history within five years prior to diagnosis or reference date. 
2 PSA at diagnosis for cases and measured at interview date for controls. 
Table 2. Risk of prostate cancer and disease aggressiveness1 associated with two SNPs in the MLH1 gene2 
 Controls All cases Less aggressive cases More aggressive cases 
 (n=1,351)3 (n=1,458)3 (n=967)3 (n=491)3 
SNP n (%) n % OR4 95% CI p n % OR4 95% CI n % OR4 95% CI 
rs9852810, chr7:115949965 
 GG 410 (33.1) 364 (28.9) 1.00 Reference  260 (30.9) 1.00 Reference 104 (24.9) 1.00 Reference 
 GA 601 (48.5) 651 (51.8) 1.21 1.02 1.45 427 (50.8) 1.12 0.91 1.36 224 (53.7) 1.46 1.12 1.91 
 AA 228 (18.4) 243 (19.3) 1.20 0.96 1.51 0.09 154 (18.3) 1.06 0.82 1.37 89 (21.3) 1.54 1.11 2.13 
 GA/AA 829 (66.9) 894 (71.1) 1.21 1.02 1.44 0.03 581 (69.1) 1.10 0.91 1.33 313 (75.1) 1.49 1.15 1.91 
rs1799977, chr7:115969290 
 TT 607 (49.1) 578 (46.2) 1.00 Reference  406 (48.5) 1.00 Reference 172 (41.7) 1.00 Reference 
 CT 514 (41.6) 555 (44.4) 1.13 0.96 1.33 357 (42.6) 1.04 0.86 1.25 198 (47.9) 1.35 1.07 1.71 
 CC 115 (9.3) 118 (9.4) 1.07 0.81 1.42 0.35 75 (9.0) 0.96 0.7 1.32 43 (10.4) 1.33 0.90 1.96 
 CT/CC 629 (50.9) 673 (53.8) 1.12 0.96 1.31 0.16 432 (51.6) 1.02 0.86 1.22 241 (58.4) 1.35 1.08 1.69 
SNP=single nucleotide polymorphism; OR=odds ratio; CI=confidence interval 
1 More aggressive PC is defined by a Gleason score of 7(4+3) or 8-10, regional or distant tumor stage, or a diagnostic PSA value >20 ng/ml. 
2 Among Caucasian cases and controls only. 
3 Total number of cases and controls vary by SNP due to missing genotype data. 
4 Adjusted for age at reference date. 
5 The first p-value is the test for trend using the co-dominant model; the second p-value is for the dominant model. 
 
 
Table 3. Risk of prostate cancer recurrence and death associated with two SNPs in the MLH1 gene1 
 Risk of recurrence Risk of death 
SNP n2 
no. who 
recurred3 (%) 
median time to 
recurrence/ 
censorship 
(years) HR4 95% CI p n 
no. who died 
of PC (%) HR4 
95% CI 
 p 
rs9852810, chr7:1159499650  
 GG 115 24 (20.9) 9.0 1.00 Reference 0.007 364 13 (3.6) 1.00 Reference 0.42  GA/AA 320 110 (34.4) 8.6 1.83 1.18 2.86 894 43 (4.8) 1.29 0.69 2.4
rs1799977, chr7:115969290  
 TT 195 55 (28.2) 8.9 1.00 Reference  578 25 (4.3) 1.00 Reference 0.74  CT/CC 238 79 (33.2) 8.7 1.22 0.86 1.72 0.260 673 32 (4.8) 1.09 0.65 1.84
HR=hazard ratio; CI=confidence interval  
1 Among Caucasian cases only. 
2 Cases diagnosed with local or regional disease who completed a follow-up survey or died of prostate cancer before Dec. 31, 2005.  
3 Recurrence is defined as at least one of the following: positive bone scan, CT, MRI, or biopsy showing PC after primary treatment; biochemical 
failure after RP as primary treatment (PSA ≥0.2 ng/mL); biochemical failure after RT as primary treatment (nadir PSA +2 ng/mL); ADT as 
secondary treatment or a rising PSA on ADT; or RT as secondary treatment. 
4 Risk of recurrence or death, respectively, among PC patients with the at-risk allele relative to PC patients homozygous for the wildtype allele.  
 
 
Supplemental data. Prostate cancer risk associated with SNPs in the MLH1, 
MSH2, and PMS2 genes, by race 
Genotype 
Cases 
(n=1,458)1 
Controls 
(n=1,351)1 OR2 95% CI p3 
n (%) n (%) 
Caucasians 
MLH1 
rs9852810, chr7:115949965 
   GG 364 (28.9) 410 (33.1) 1.00 Reference  
   GA 651 (51.8) 601 (48.5) 1.21 1.02 1.45  
   AA 243 (19.3) 228 (18.4) 1.20 0.96 1.51 0.09 
   GA or AA 894 (71.1) 829 (66.9) 1.21 1.02 1.44 0.03 
rs749072, chr7:115962947 
   TT 686 (55.7) 679 (56.1) 1.00 Reference  
   TC 468 (38.0) 439 (36.3) 1.06 0.89 1.25  
   CC 77 (6.3) 93 (7.7) 0.81 0.59 1.12 0.28 
   TC or CC 545 (44.3) 532 (43.9) 1.01 0.86 1.19 0.86 
rs1540354, chr7:115965061 
   AA 843 (67.2) 824 (66.9) 1.00 Reference  
   GA 370 (29.5) 357 (29.0) 1.02 0.85 1.21  
   GG 42 (3.4) 51 (4.1) 0.81 0.53 1.24 0.59 
   GA or GG 412 (32.8) 408 (33.1) 0.99 0.84 1.17 0.32 
rs1799977, chr7:115969290 
   TT 578 (46.2) 607 (49.1) 1.00 Reference  
   CT 555 (44.4) 514 (41.6) 1.13 0.96 1.33  
   CC 118 (9.4) 115 (9.3) 1.07 0.81 1.42 0.35 
   CT or CC 673 (53.8) 629 (50.9) 1.12 0.96 1.31 0.16 
rs9311149, chr7:1159734774 
   GG 342 (27.1) 307 (24.9) 1.00 Reference  
   GA 638 (50.5) 607 (49.2) 0.94 0.78 1.14  
   AA 284 (22.5) 320 (25.9) 0.80 0.64 1.00 0.13 
   GA or AA 922 (72.9) 927 (75.1) 0.89 0.75 1.07 0.20 
MSH2 
rs4583514, chr7:115977833 
   CC 482 (38.2) 470 (38.1) 1.00 Reference  
   CT 594 (47.1) 591 (47.9) 0.98 0.82 1.16  
   TT 185 (14.7) 173 (14.0) 1.05 0.82 1.34 0.86 
   CT or TT 779 (61.8) 764 (61.9) 0.99 0.85 1.17 0.97 
rs3732183, chr7:115986931 
   CC 666 (53.0) 654 (53.3) 1.00 Reference  
   CA 497 (39.6) 491 (40.0) 0.99 0.84 1.17  
   AA 93 (7.4) 82 (6.7) 1.12 0.82 1.53 0.77 
   CA or AA 590 (47.0) 573 (46.7) 1.01 0.86 1.18 0.86 
rs10495944, chr7:115987328 
   TT 959 (75.8) 931 (75.1) 1.00 Reference  
   CT 289 (22.8) 294 (23.7) 0.96 0.79 1.15  
   CC 18 (1.4) 15 (1.2) 1.18 0.59 2.35 0.80 
   CT or CC 307 (24.3) 309 (24.9) 0.97 0.81 1.16 0.74 
rs4608577, chr7:115987616 
   GG 864 (68.1) 844 (68.1) 1.00 Reference  
   GA 369 (29.1) 366 (29.5) 0.99 0.83 1.17  
   AA 35 (2.8) 29 (2.3) 1.18 0.71 1.95 0.80 
   GA or AA 404 (31.9) 395 (31.9) 1.00 0.85 1.18 0.98 
rs17036577, chr7:115987823 
   CC 1,067 (84.2) 1,017 (81.9) 1.00 Reference  
   CT 191 (15.1) 215 (17.3) 0.85 0.68 1.05  
   TT 10 (0.8) 10 (0.8) 0.99 0.41 2.40 0.31 
   CT or TT 201 (15.9) 225 (18.1) 0.85 0.69 1.05 0.13 
rs1863332, chr7:1159247624 
   GG 1,033 (84.0) 1,020 (83.6) 1.00 Reference  
   GA 189 (15.4) 190 (15.6) 0.98 0.79 1.23  
   AA 8 (0.7) 10 (0.8) 0.80 0.31 2.03 0.88 
   GA or AA 197 (16.0) 200 (16.4) 0.97 0.79 1.21 0.80 
rs1981929, chr7:115924913 
   AA 472 (37.2) 464 (37.3) 1.00 Reference  
   GA 585 (46.1) 589 (47.4) 0.97 0.82 1.16  
   GG 212 (16.7) 190 (15.3) 1.09 0.86 1.38 0.63 
   GA or GG 797 (62.8) 779 (62.7) 1.00 0.85 1.18 0.99 
rs4638843, chr7:115925128 
   TT 985 (77.6) 956 (77.0) 1.00 Reference  
   GT 266 (21.0) 267 (21.5) 0.95 0.79 1.16  
   GG 18 (1.4) 19 (1.5) 0.91 0.48 1.75 0.88 
   GT or GG 284 (22.4) 286 (23.0) 0.95 0.79 1.15 0.63 
rs4952887, chr7:115933310 
   CC 1,052 (83.0) 1,040 (83.9) 1.00 Reference  
   CG 203 (16.0) 189 (15.2) 1.07 0.86 1.33  
   GG 13 (1.0) 11 (0.9) 1.20 0.53 2.68 0.79 
   CG or GG 216 (17.0) 200 (16.1) 1.08 0.87 1.33 0.53 
rs10191478, chr7:115935144 
   CC 393 (31.2) 390 (31.5) 1.00 Reference  
   GC 635 (50.4) 620 (50.0) 1.02 0.85 1.22  
   GG 232 (18.4) 230 (18.6) 1.01 0.80 1.27 0.98 
   GC or GG 867 (68.8) 850 (68.6) 1.02 0.86 1.20 0.85 
PMS2 
rs2286680, chr7:115935606 
   TT 959 (76.1) 923 (74.4) 1.00 Reference  
   GT 280 (22.2) 291 (23.5) 0.93 0.77 1.12  
   GG 21 (1.7) 27 (2.2) 0.75 0.42 1.33 0.47 
   GT or GG 301 (23.9) 318 (25.6) 0.91 0.76 1.10 0.32 
rs6463524, chr7:115938105 
   TT 813 (64.0) 791 (63.7) 1.00 Reference  
   CT 411 (32.4) 409 (33.0) 0.98 0.83 1.67  
   CC 46 (3.6) 41 (3.3) 1.08 0.70 1.67 0.91 
   CT or CC 457 (36.0) 450 (36.3) 0.99 0.84 1.16 0.91 
rs2345060, chr7:115938188 
   CC 703 (55.6) 693 (55.8) 1.00 Reference  
   CA 489 (38.7) 474 (38.2) 1.02 0.86 1.20  
   AA 73 (5.8) 74 (6.0) 0.97 0.69 1.37 0.96 
   CA or AA 562 (44.4) 548 (44.2) 1.01 0.86 1.18 0.90 
African Americans
MLH1 
rs9852810, chr7:115949965 
   GG 96 (66.2) 44 (55.7) 1.00 Reference  
   GA 42 (29.0) 32 (40.5) 0.57 0.31 1.07  
   AA 7 (4.8) 3 (3.8) 0.98 0.22 4.41 0.21 
   GA or AA 49 (33.8) 35 (44.3) 0.61 0.33 1.11 0.10 
rs749072, chr7:115962947 
   TT 89 (62.7) 49 (62.0) 1.00 Reference  
   TC 47 (33.1) 23 (29.1) 1.18 0.62 2.25  
   CC 6 (4.2) 7 (8.9) 0.47 0.14 1.59 0.37 
   TC or CC 53 (37.3) 30 (38.0) 1.01 0.56 1.85 0.97 
rs1540354, chr7:115965061 
   AA 129 (89.6) 71 (89.9) 1.00 Reference  
   GA 15 (10.4) 8 (10.1) 0.81 0.31 2.16  
   GG -- -- -- -- -- -- -- 0.68 
   GA or GG 15 (10.4) 8 (10.1) 0.81 0.31 2.16 0.68 
rs1799977, chr7:115969290 
   TT 123 (86.0) 67 (83.8) 1.00 Reference  
   CT 17 (11.9) 13 (16.3) 0.61 0.26 1.40  
   CC 3 (2.1) -- -- -- -- -- 0.50 
   CT or CC 20 (14.0) 13 (16.3) 0.72 0.32 1.62 0.43 
rs9311149, chr7:115973477 
   GG 50 (34.5) 28 (35.9) 1.00 Reference  
   GA 72 (49.7) 35 (44.9) 1.18 0.61 2.26  
   AA 23 (15.9) 15 (19.2) 0.83 0.35 1.94 0.68 
   GA or AA 95 (65.5) 50 (64.1) 1.07 0.58 1.98 0.83 
MSH2 
rs4583514, chr7:115977833 
   CC 11 (7.6) 2 (2.6) 1.00 Reference  
   CT 60 (41.7) 39 (50.0) 0.37 0.07 1.84  
   TT 73 (50.7) 37 (47.4) 0.45 0.09 2.25 0.43 
   CT or TT 133 (92.4) 76 (97.4) 0.41 0.08 1.99 0.27 
rs3732183, chr7:115986931 
   CC 23 (16.1) 5 (6.3) 1.00 Reference  
   CA 71 (49.7) 48 (60.8) 0.38 0.13 1.13  
   AA 49 (34.3) 26 (32.9) 0.50 0.16 1.53 0.20 
   CA or AA 120 (83.9) 74 (93.7) 0.42 0.15 1.51 0.11 
rs10495944, chr7:1159873284 
   TT 137 (94.5) 75 (93.75) 1.00 Reference  
   CT 7 (4.8) 5 (6.3) 0.71 0.20 2.54  
   CC 1 (0.7) -- -- -- -- -- 0.87 
   CT or CC 8 (5.5) 5 (6.3) 0.80 0.23 2.76 0.73 
rs4608577, chr7:115987616 
   GG 83 (62.9) 42 (57.5) 1.00 Reference  
   GA 42 (31.8) 26 (35.6) 0.91 0.48 1.76  
   AA 7 (5.3) 5 (6.9) 1.05 0.29 3.80 0.96 
   GA or AA 49 (37.1) 31 (42.5) 0.93 0.50 1.73 0.83 
rs17036577, chr7:115987823 
   CC 114 (78.6) 66 (82.5) 1.00 Reference  
   CT 27 (18.6) 14 (17.5) 1.03 0.48 2.19  
   TT 4 (2.8) -- -- -- -- -- 0.99 
   CT or TT 31 (21.4) 14 (17.5) 1.22 0.58 2.55 0.60 
rs1863332, chr7:115924762 
   GG 100 (69.0) 52 (65.8) 1.00 Reference  
   GA 39 (26.9) 25 (31.7) 0.71 0.37 1.36  
   AA 6 (4.1) 2 (2.5) 1.68 0.30 9.24 0.45 
   GA or AA 45 (31.0) 27 (34.2) 0.78 0.42 1.45 0.43 
rs1981929, chr7:115924913 
   AA 113 (77.9) 67 (83.8) 1.00 Reference  
   GA 31 (21.4) 12 (15.0) 1.69 0.77 3.72  
   GG 1 (0.7) 1 (1.3) 0.26 0.01 5.31 0.28 
   GA or GG 32 (22.1) 13 (16.3) 1.54 0.72 3.30 0.27 
rs4638843, chr7:115925128 
   TT 132 (91.0) 77 (96.3) 1.00 Reference  
   GT 13 (9.0) 3 (3.8) 3.21 0.84 12.3  
   GG -- -- -- -- -- -- -- 0.09 
   GT or GG 13 (9.0) 3 (3.8) 3.21 0.84 12.3 0.09 
rs4952887, chr7:115933310 
   CC 114 (78.6) 61 (77.2) 1.00 Reference  
   CG 31 (21.4) 18 (22.8) 0.71 0.34 1.46  
   GG -- -- -- -- -- -- -- 0.35 
   CG or GG 31 (21.4) 18 (22.8) 0.71 0.34 1.46 0.35 
rs10191478, chr7:115935144 
   CC 3 (2.1) 2 (2.5) 1.00 Reference  
   GC 53 (36.8) 20 (25.3) 3.68 0.46 29.37  
   GG 88 (61.1) 57 (72.2) 1.95 0.26 14.81 0.12 
   GC or GG 141 (97.9) 77 (97.5) 2.34 0.31 17.47 0.41 
PMS2 
rs2286680, chr7:115935606 
   TT 96 (66.2) 47 (58.8) 1.00 Reference  
   GT 44 (30.3) 28 (35.0) 0.71 0.38 1.33  
   GG 5 (3.5) 5 (6.3) 0.49 0.12 1.90 0.39 
   GT or GG 49 (33.8) 33 (41.3) 0.68 0.37 1.23 0.20 
rs6463524, chr7:115938105 
   TT 108 (74.5) 54 (67.5) 1.00 Reference  
   CT 35 (24.1) 23 (28.8) 0.73 0.38 1.41  
   CC 2 (1.4) 3 (3.8) 0.37 0.05 2.66 0.43 
   CT or CC 37 (25.5) 26 (32.5) 0.69 0.37 1.31 0.26 
rs2345060, chr7:115938188 
   CC 98 (67.6) 48 (60.0) 1.00 Reference  
   CA 40 (27.6) 26 (32.5) 0.70 0.37 1.34  
   AA 7 (4.8) 6 (7.5) 0.64 0.19 2.12 0.48 
   CA or AA 47 (32.4) 32 (40.0) 0.69 0.38 1.27 0.23 
SNP=single nucleotide polymorphism; OR=odds ratio; CI=confidence interval 
1 Total number of cases and controls vary by SNP due to missing genotype data. 
2 Adjusted for age at reference date. 
3 The first p-value is the test for trend using the codominant model; the second p-value is for the dominant 
model. 
